DNTH vs MCK · rev $6.2M vs P/E 20, rev $403.43B
Dianthus Therapeutics Inc. (DNTH) versus McKesson Corporation (MCK) — a side-by-side from cached financials, not a winner call.
Dianthus Therapeutics Inc. (DNTH) is a biotechnology company listed on US.
McKesson Corporation (MCK) is a medical distribution company listed on NYSE.
Latest reported DNTH revenue for 2024-12-31 was $6.2M. Net income was -$85.0M. Revenue was up 120.6% from 2023-12-31 to 2024-12-31. DNTH currently screens at market cap $4.40B.
Latest reported MCK revenue for 2026-03-31 was $403.43B. Net income was $4.76B. Revenue was up 12.4% from 2025-03-31 to 2026-03-31. MCK currently screens at market cap $91.30B and trailing P/E 20.3.
DNTH currently screens at market cap $4.40B. MCK currently screens at market cap $91.30B and trailing P/E 20.3.
Not investment advice. Open the DNTH and MCK stock pages for the full models.
Not investment advice.